Osiris stem cell platform success hinges on 2 trials
Thursday, September 3, 2009 - 15:14
in Health & Medicine
BANGALORE (Reuters) - Osiris Therapeutics Inc, which is developing a drug to treat a rare condition that affects bone marrow transplant patients, is poised to unveil results from a late-stage trial that could pave the way for the first approved drug in that indication and instill investor confidence in the company.